Nasus Pharma presents phase 2 data on intranasal epinephrine

Nasus Pharma (NYSE:NSRX) presented Phase 2 study data for NS002, an intranasal epinephrine powder, showing faster therapeutic threshold reach than autoinjectors. No serious adverse events were reported. The company plans a pivotal study by late 2026, with results expected in Q1 2027. NS002 is being developed as a needle-free alternative for anaphylaxis treatment.

Original reporting
Published Nov 17, 2026, 1:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$NSRX
Bullish
medium confidence
Mentioned
$NSRX
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NSRXBullishMed
01

Why it matters

The disclosed Phase 2 findings and the stated plan to start a pivotal study before end-2026 create a near-to-medium term catalyst path, potentially improving valuation expectations for clinical-stage development progress.

02

Market read

Traders may reassess NSRX based on incremental clinical evidence and a more specific development timeline toward pivotal initiation and a Q1 2027 topline readout.

03

What to watch

No serious adverse events were reported, but the article does not quantify efficacy outcomes beyond the 100 pg/mL threshold or provide effect sizes, sample size, or statistical significance details.

Relevance 7/10Novelty 6/10Timing: conference presentation now, with pivotal-study initiation and Q1 2027 topline as next milestones

Background

Nasus Pharma is developing NS002, an investigational intranasal epinephrine powder intended as a needle-free alternative to epinephrine autoinjectors.

Company-level read

Ticker impact

$NSRXBullishMedium confidence
Context

Nasus Pharma presented Phase 2 NP007 data for intranasal epinephrine NS002, showing faster time to a 100 pg/mL threshold than an autoinjector.

Expected impact

Likely modest upside bias as investors price improved clinical momentum and the stated plan for a pivotal study before end-2026.

Evidence & confidence

The article provides specific Phase 2 comparative findings (speed to threshold, potential superiority in severe nasal congestion) plus a concrete development timeline (pivotal initiation before end-2026, topline in Q1 2027).

Market effects

Reinforces investor interest in intranasal, needle-free emergency therapeutics and delivery-platform differentiation in acute care.

Limited direct regional market impact; primarily affects US-listed biotech sentiment.

Moderate global relevance for anaphylaxis treatment innovation, but no cross-border regulatory or partnership decision disclosed.

Counterpoint

Phase 2 posters and threshold-speed metrics may not translate into clinically meaningful endpoints, so the market may discount the results until pivotal data.

Key entities

  • Nasus Pharma Ltd.

    NYSE-listed clinical-stage biotech presenting Phase 2 NP007 data for intranasal epinephrine NS002 and outlining pivotal-study timing.

  • NS002

    Investigational intranasal epinephrine powder for anaphylaxis, evaluated in Phase 2 NP007.

  • NP007 Phase 2 study

    Phase 2 trial whose results were presented at an allergy conference, including comparisons versus an autoinjector.

Related articles

$NSRXMedAI 8/10

Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron

Nasus Pharma (NYSE: NSRX) has enrolled and dosed the first patient in a Phase 1 trial for NS003, its intranasal ondansetron formulation. Pre-clinical studies showed NS003's PK profile was comparable to IV ondansetron, with a favorable safety profile. The company aims to announce topline PK data before year-end and initiate a pivotal NS002 study for anaphylaxis in Q4. Ondansetron is widely used for chemotherapy-induced nausea and vomiting, with peak sales exceeding $1.5 billion in 2023.

$NSRXMed

Nasus Pharma Ltd (NSRX): Financial results for H1 2026

Nasus Pharma Ltd (NSRX) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update Appointed Pharma Industry Veteran Brendan O’Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, August

$VERUMed

Veru presents data on enobosarm for obesity treatment

Veru Inc. (VERU) presented Phase 2b QUALITY study data at ObesityWeek 2026, showing enobosarm 3mg plus semaglutide helped patients aged 65+ with obesity gain lean mass and maintain physical function. The Phase 2b PLATEAU trial, with 239 patients, is ongoing, with interim data expected in Q1 2027. Veru has a clinical supply agreement with Novo Nordisk and a U.S. patent for the combination therapy.

$MTVAMed

MetaVia completes phase 1 trial of liver disease drug DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 trial for DA-1726, a drug for liver-related cardiometabolic diseases. The trial extended treatment to 24 weeks, showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for late 2027. DA-1726 is a once-weekly subcutaneous treatment.

$MTVAMed

MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 clinical trial for DA-1726, a novel GLP-1/glucagon dual-receptor agonist. The treatment period was extended to 24 weeks, with encouraging safety and tolerability data. Part 3B interim results showed a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for H2 2027.